Effect of Pitavastatin on Coronary Flow Reserve in Hypertensive Patients

Asan Medical Center85 enrolled

Overview

Although statins reduce cardiac events in hypertensive patients with cardiovascular risk factors, the effect of statins on coronary flow reserve (CFR) has not been examined in such patients. The investigators hypothesize that pitavastatin added to standard antihypertensive therapy will be superior to placebo in improving CFR in hypertensive patients with cardiovascular risk, and try to examine this hypothesis in a double-blind, randomized comparison study using Doppler echocardiography.

Statin treatment improves coronary flow reserve (CFR) and decreases cardiac morbidity and mortality in patients with coronary artery disease (CAD) and hypercholesterolemia. Endothelial dysfunction and impairment in coronary microcirculation is also observed in hypertensive patients with cardiovascular risk factors. However, the measurement of CFR has rarely been performed in hypertensive patients without CAD, because CFR could be invasively measured using a Doppler guide wire in a cardiac catheterization laboratory. Recent advances in echocardiographic imaging techniques have made it possible to measure coronary flow velocity and CFR, which highly correlates with the CFR measured by invasive means. Lipid lowering with a statin provided beneficial effects in patients with average levels of serum total cholesterol in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA) study conducted in hypertensive patients at cardiovascular risk. Improvements in endothelial dysfunction and CFR may be related to the beneficial effects of statins in hypertensive patients without hypercholesterolemia, but the effect of statins on CFR has not been examined in such patients. Accordingly, the investigators try to examine the hypothesis that pitavastatin added to standard antihypertensive therapy in hypertensive patients with cardiovascular risk will be superior to placebo in improving CFR in a double-blind, randomized comparison study using Doppler echocardiography.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

Conditions

Hypertension Cardiovascular Risk

Interventions

PitavastatinDRUG

statin

ControlOTHER

Life style modification alone

Eligibility

Sex: ALLMin age: 35 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Controlled Hypertension: treated SBP\<140 mmHg and DBP\<90 mmHg * LDL cholesterol ≥ 130mg/dL * Patients with statin-naive state, defined as receiving no statin therapy for more than 6 months during the previous 12 months. * Any 1 of these cardiovascular risk factors required: smoking, age over 55 (men) or 65 (women), history of cerebrovascular event, family history of early CHD before age 55, HDL cholesterol \< 40 mg/dL Exclusion Criteria: * A previous history of intolerance or hypersensitivity to statins * Uncontrolled hypertension; SBP≥140 mmHg or DBP≥90 mmHg * Previous MI or currently treated angina pectoris * Stroke, TIA \< 3 months * Secondary hypertension * Fasting serum triglyceride \> 500 mg/dL * Clinical congestive heart failure * Uncontrolled arrhythmia * Left ventricular hypertrophy: LV mass index \>134g/m2 (male) or \>110g/m2 (female) * Concomitant clinically important hematological, gastrointestinal, hepatic, renal or other disease * Pregnant or lactating women and those of child-bearing potential * Diabetes * Peripheral vascular disease * Unwillingness or inability to comply with the procedures described in this protocol

Locations (1)

Asan Medical Center

Seoul, South Korea

Outcomes

Primary Outcomes

change in the CFR value

Change of coronary flow velocity reserve from baseline to 1 year follow-up. For each patient, the averaged value of coronary flow velocity reserve will be obtained at baseline and 1 year follow-up.

Time frame: 12 months

Difference in mean CFR value

DIfference in CFR value at 12 month follow-up between pitavastatin and placebo arm

Time frame: 12 months

Secondary Outcomes

change of CRP

Change of CRP from baseline to 1 year follow-up.

Time frame: 12 months

Change of LDL-cholesterol

Change of LDL-cholesterol from baseline to 1 year follow-up.

Time frame: 12 months

Change of averaged peak diastolic velocity

Change of averaged peak diastolic velocity from baseline to study end.

Time frame: 12 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.